Key facts
- This page summarizes John Johnson's Form 4 filing for Axogen, Inc. (AXGN).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 03 Jun 2022, 16:14.
John Johnson - 01 Jun 2022 Form 4 Insider Report for Axogen, Inc. (AXGN)
- Reporting relationship
- Director
- Issuer ticker
- AXGN
- Reported as of
- 01 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jun 2022, 16:14:05 UTC
- Prior SEC filing
- 20 Dec 2022
- Next SEC filing
- 09 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- John Johnson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John Johnson filed Form 4 for Axogen, Inc. (AXGN) on 03 Jun 2022.
Change
- Previous filing in this sequence was filed on 20 Dec 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AXGN
transaction
Derivative
Employee Stock Option (right to purchase)
Award
- Transaction value
- $0
- Shares
- +11,811
- Change %
- Price
- $0.000000
- Shares after
- 11,811
- Date
- 01 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,811
- Exercise price
- $9.29
- Footnotes
- F1
AXGN
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +6,459
- Change %
- Price
- $0.000000
- Shares after
- 6,459
- Date
- 01 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,459
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.